2006 Lonzeal Pharmaceuticals was established

2008 The production base of Lonzeal Pharmaceuticals was put into operation

2010 Obtained the GMP certificate of raw materials from the State Food and Drug Administration of China

2012 Passed the GMP on-site inspection of the World Health Organization

From 2012 to 2015, API products have been registered in Brazil, Russia, South Africa and other countries

2017 Passed the GMP on-site inspection of multiple anti-AIDS APIs by the World Health Organization

2018 Zero defect passed the US FDA's API GMP on-site inspection

2019 Anti-AIDS and hepatitis B preparation products took the lead in passing the consistency evaluation

2021 Paroxetine Hydrochloride, Tenofovir Alafenamide Fumarate, and Pregabalin passed the consistency evaluation and obtained drug registration approval